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DIABETES—Clinical Outcomes/Healthcare Policy
PDB1
RELATION BETWEEN MEDICATION
COMPLIANCE AND GLUCOSE CONTROL IN
PATIENTS WITH TYPE 2 DIABETES
Shi SG1, Knight T1, Livengood KB2, Lubowski T2,Walden S2,
Nichol MB1
1University of Southern California, Los Angeles, CA, USA;
2Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: To determine whether diabetes patients
who are more compliant with their medication therapy
tend to have a better glucose control. METHODS: The
analysis is based on clinical and survey data of 301
patients from 6 clinical centers in different regions of 
the U.S. Medication compliance is quantiﬁed from the
Morisky score, and the A1c fraction of glycosylated
hemoglobin (HbA1c) from a recent lab test is used to
measure glucose control. The relation between the two is
established with a general linear model controlling for a
set of covariates. The covariates include diabetes severity
proxies (the number of anti-diabetic agents, insulin vs.
non-insulin regimen, diabetes complications), length of
time with diabetes, demographic factors (age, gender, eth-
nicity), body mass index score (BMI), education level,
payment source, and clinic site. RESULTS: About 70%
of the diabetes patients in the sample were considered
compliant (Morisky score of 3 or greater). Compliance
patients had an HbA1c score 10% better or lower than
non-compliant patients, adjusted for covariates (p =
0.0003). As a by-product of the analysis, each additional
anti-diabetes medication was seen to be associated with
3.6% increase in HbA1c score. CONCLUSIONS: Self-
reported compliance with anti-diabetic medications
appears to be related to HbA1c. Future research should
correlate self-reported compliance with pharmacy claims,
and should be expanded to a different sample.
PDB2
IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C)
TESTING AND ANALYSIS OF PARTICIPANT-
REPORTED RESULTS IN CAREPATTERNS® FOR
DIABETES PROGRAM
Slezak J, Hu L, Berger J
Caremark, Northbrook, IL, USA
OBJECTIVES: HbAlc is considered a cornerstone of dia-
betic care, a recognized clinical measure within diabetes
disease management and an important tool to help
patients assess their own diabetes management. This
study examines the frequency of participant-reported
HbAlc testing and improvement of results after the
Carepatterns® intervention. METHODS: Study partici-
pants enrolled in the program and were enrolled contin-
uously for at least 1 calendar year beginning in 2000.
They were asked if they received the Alc test from their
physician during their initial and annual telephonic
assessment calls. The result of the test was collected if
available. If the participant did not receive the test or did
not know if they had, they were educated on its impor-
tance. Participants were encouraged to ask their doctor
about testing and to discuss their results. Data were com-
piled and a 95% conﬁdence interval and corresponding
p-value was computed from the formula for the differ-
ence between 2 independent proportions and paired 
t-tests. RESULTS: Of 4257 study participants, 69% ini-
tially reported receiving an HbAlc test, and 83% at
annual for a D 14%, (95% CI 12%-16%, p < 0.05). An
analysis of 373 participant reported test values was per-
formed using a matched paired-t test when the value of
the test was provided during initial and annual assess-
ment. At initial assessment, mean test result of 7.02% was
reported and during their annual call, 6.76%. The mean
change 0.26 (95% CI 0.16 to 0.37 p < .05) was sig-
niﬁcant. CONCLUSIONS: These ﬁndings show that
CarePatterns® for diabetes program enrollees are
improving their compliance with the HbA1c test as well
as lowering their participant-reported test values after
participating in the program.
PDB3
EFFICACY OF INSULIN GLARGINE IN PATIENTS
WITH TYPE 1 AND 2 DIABETES
Plauschinat CA, Cryar AK, Godley PJ, Nguyen AB,
Browne BA
Scott & White Memorial Hospital,Temple,TX, USA
OBJECTIVES: Insulin glargine is a biosynthetic insulin
analog with a prolonged duration of action. Our objec-
tive is to determine the efﬁcacy of insulin glargine regard-
ing glycemic control in patients with Type 1 and 2
diabetes. A secondary objective is to determine potential
cost savings, if any, that may result from the use of insulin
glargine as an alternative to oral hypoglycemic agents in
patients with Type 2 diabetes. METHODS: A total of 135
patients with a diagnosis of Type 1 or 2 diabetes initiated
on insulin glargine by institutional endocrinologists from
April 2001 to September 2001 were included in this
study. Medical and pharmacy claims databases were ret-
rospectively analyzed 1 year pre- to 1 year post-initiation
of insulin glargine. Hemoglobin A1c (HbA1c), frequency
of hypoglycemic adverse events, and utilization of oral
hypoglycemic agents were evaluated. RESULTS: Average
HbA1c signiﬁcantly decreased by 0.31% from 8.48%
pre-glargine to 8.16% post-glargine (P = 0.012). The
overall frequency of hypoglycemia and nonsevere hypo-
glycemia were both signiﬁcantly lower in the post-
glargine period (69% vs. 36%, P < 0.001 and 38% vs.
19%, P < 0.01, respectively). In patients with Type 2 dia-
betes, a trend toward decreased utilization of oral hypo-
glycemic agents in the post-glargine period was observed
in the sulfonylureas, thiazoladinediones, and biguanides
(58.5% vs. 39%, P < 0.01). The use of insulin glargine
as an alternative to oral hypoglycemic agents resulted in
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a cost savings of $21,200 per year in 41 patients with
Type 2 diabetes. CONCLUSION: Control of diabetes as
measured by the HbA1c was signiﬁcantly better after 
the initiation of insulin glargine with beneﬁts including a
decreased overall frequency of hypoglycemia. Addition-
ally, insulin glargine may be a cost-effective alternative 
to increases in the dose or number of oral hypoglycemic
agents in patients with Type 2 diabetes. Conclusive evi-
dence on the efﬁcacy of insulin glargine will come from
larger cohort studies.
PDB4
OBTAINING QUALITY REAL-WORLD
TREATMENT DATA FOR ECONOMIC 
MODELS: METHODOLOGY AND RESULTS 
OF A WOUND CARE MEDICAL RECORD
ABSTRACTION STUDY
Hazard EH, Klingman CD, Semroc GN
ValueMedics Research, LLC, Alexandria,VA, USA
OBJECTIVES: Although clinical trial data are often used
in economic models, they may not reﬂect real-world 
utilization and outcomes of therapy. To determine real-
world resource use and outcomes of diabetic foot ulcer
(DFU) care using Graftskin (a living bi-layered skin sub-
stitute) and to supplement clinical data for a DFU treat-
ment model, a medical record abstraction study was
conducted at 21 U.S. treatment centers that practice good
wound care (GWC). METHODS: Two physician samples
were recruited: a Graftskin sample (physicians who fre-
quently use and receive reimbursement for Graftskin 
in the treatment of DFUs), and a non-Graftskin sample
(physicians who treat DFU using GWC and who do not
receive reimbursement for using Graftskin). Separate
abstraction forms were developed for each sample, sent
by mail to the treatment centers, completed by center
staff, and returned via fax. The center received a small
honorarium per completed form. RESULTS: Twenty-one
centers and 166 cases (83 Graftskin and 83 GWC) were
included in the analysis. Graftskin patients had more
severe DFUs (21cm2) than those in the Graftskin pivotal
trial (2.97cm2), which compared GWC plus Graftskin to
GWC alone. In addition, Graftskin patients had more
severe DFUs than the GWC patients in this study 
(11cm2). The mean number of Graftskin applications was
much lower in this study (1.27 applications) than in the
Graftskin pivotal trial (3.9 applications). Moreover, in
this study, the incidence of severe adverse events was sig-
niﬁcantly lower with Graftskin (37%) than with GWC
(52%), even when controlling for ulcer severity (p =
0.006). CONCLUSION: In actual practice, the number
of Graftskin applications was considerably lower and
DFU severity was substantially higher than in the 
Graftskin pivotal clinical trial. These data were applied
to the DFU treatment model, which yielded improved
estimates of the real-world impact of utilizing Graftskin
versus GWC.
PDB5
MEDICATION COMPLIANCE IN TYPE 2
DIABETES SUBJECTS: RETROSPECTIVE 
DATA ANALYSIS
Rajagopalan R1, Joyce A2, Ollendorf D2, Murray FT1
1Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL,
USA; 2PharMetrics Inc, Watertown, MA, USA
OBJECTIVES: Medication adherence and compliance are
problems in young and elderly patients. With the increas-
ing number of prescribed drugs, compliance drops and
the number of adverse events increases. Furthermore,
elderly patients are likely to have several co-morbidities,
which could also affect their drug-consumption behavior
considerably. In this study, our objective was to evaluate
the compliance of anti-diabetic medication therapy in
subjects with type 2 diabetes mellitus who initiated treat-
ment with one of various oral anti-diabetic drugs or
insulin. METHODS: Data for this study spanned the
period January 1, 1995 to March 31, 2002 and were
obtained from the Pharmetrics Patient-Centric Database,
which is comprised of fully adjudicated medical and phar-
maceutical claims for over 29 million unique patients
from 52 health plans across the US. Patients with Type 2
diabetes mellitus (n = 199,000) were classiﬁed into mutu-
ally exclusive treatment groups based on the therapy ﬁrst
received during the period of observation. Compliance
rate was determined by the total number of days between
ﬁrst ﬁlled and last ﬁlled prescription plus days ﬁlled in the
last prescription, divided by last ﬁll date and the ﬁrst ﬁll
date plus a 90-day gap. RESULTS: The pioglitazone
group (n = 2,730) ranked the highest in compliance with
a mean of 85% (89% in the 55–64 age group) and a
median of 91% compared to a mean compliance of 62%
in the insulin group (n = 27,274) (P < 0.001) and 81% in
the metformin group (n = 52,469) (P = 0.001). Similar
results were found in newly diagnosed subjects. One-third
of all pioglitazone patients added a second line therapy
for diabetes compared to 43.9% on rosiglitazone (n =
4,068). CONCLUSION: Compliance to treatment
regimen for patients taking pioglitazone was higher than
for patients on other anti-diabetic medications.
PDB6
FACTORS ASSOCIATED WITH HIGH-RISK
DIABETIC PATIENTS IN THE CALIFORNIA
MEDICAID POPULATIONS (MEDI-CAL)
Chaikledkaew U_1,Wu EQ2, Johnson KA1
1University of Southern California, Los Angeles, CA, USA;
2Analysis Group/Economics, Boston, MA, USA
OBJECTIVES: Patient risk is identiﬁed by an increase in
healthcare cost, the occurrence of hospitalization or emer-
gency room (ER) event, and a decrease in time to hospi-
talization or ER event. The purpose of this research is 
to investigate factors associated with high-risk diabetic
patients based on claims data from the California Med-
